Amylyx Pharmaceuticals Says Was Informed The CHMP Is Trending Toward A Negative Opinion On Application For Conditional Marketing Authorization For AMX0035 For Treatment Of ALS
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharmaceuticals has been informed that the CHMP is trending toward a negative opinion on the application for conditional marketing authorization for AMX0035, a treatment for ALS.
May 30, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amylyx Pharmaceuticals may face a negative opinion from the CHMP on their ALS treatment AMX0035, potentially impacting the stock price.
The Committee for Medicinal Products for Human Use (CHMP) is trending toward a negative opinion on Amylyx Pharmaceuticals' application for conditional marketing authorization for AMX0035, a treatment for ALS. This negative opinion could impact the company's ability to market and sell the product, which would likely have a negative effect on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100